145 related articles for article (PubMed ID: 31334703)
1. Effect of rosuvastatin and eicosapentaenoic acid on neoatherosclerosis: the LINK-IT Trial.
Kuroda K; Otake H; Shinohara M; Kuroda M; Tsuda S; Toba T; Nagano Y; Toh R; Ishida T; Shinke T; Hirata KI
EuroIntervention; 2019 Dec; 15(12):e1099-e1106. PubMed ID: 31334703
[TBL] [Abstract][Full Text] [Related]
2. Concomitant Use of Rosuvastatin and Eicosapentaenoic Acid Significantly Prevents Native Coronary Atherosclerotic Progression in Patients With In-Stent Neoatherosclerosis.
Sugizaki Y; Otake H; Kuroda K; Kawamori H; Toba T; Nagasawa A; Takeshige R; Nakano S; Matsuoka Y; Tanimura K; Takahashi Y; Fukuyama Y; Hirata KI
Circ J; 2020 Sep; 84(10):1826-1836. PubMed ID: 32759543
[TBL] [Abstract][Full Text] [Related]
3. Effects of Fatty Acid Therapy in Addition to Strong Statin on Coronary Plaques in Acute Coronary Syndrome: An Optical Coherence Tomography Study.
Kita Y; Watanabe M; Kamon D; Ueda T; Soeda T; Okayama S; Ishigami K; Kawata H; Horii M; Inoue F; Doi N; Okura H; Uemura S; Saito Y
J Am Heart Assoc; 2020 Aug; 9(16):e015593. PubMed ID: 32805184
[TBL] [Abstract][Full Text] [Related]
4. Stabilizing effect of combined eicosapentaenoic acid and statin therapy on coronary thin-cap fibroatheroma.
Nishio R; Shinke T; Otake H; Nakagawa M; Nagoshi R; Inoue T; Kozuki A; Hariki H; Osue T; Taniguchi Y; Iwasaki M; Hiranuma N; Konishi A; Kinutani H; Shite J; Hirata K
Atherosclerosis; 2014 May; 234(1):114-9. PubMed ID: 24637411
[TBL] [Abstract][Full Text] [Related]
5. Effects of 6-month eicosapentaenoic acid treatment on postprandial hyperglycemia, hyperlipidemia, insulin secretion ability, and concomitant endothelial dysfunction among newly-diagnosed impaired glucose metabolism patients with coronary artery disease. An open label, single blinded, prospective randomized controlled trial.
Sawada T; Tsubata H; Hashimoto N; Takabe M; Miyata T; Aoki K; Yamashita S; Oishi S; Osue T; Yokoi K; Tsukishiro Y; Onishi T; Shimane A; Taniguchi Y; Yasaka Y; Ohara T; Kawai H; Yokoyama M
Cardiovasc Diabetol; 2016 Aug; 15(1):121. PubMed ID: 27565734
[TBL] [Abstract][Full Text] [Related]
6. One-year efficacy and safety of rosuvastatin + fenofibric acid combination therapy in patients with mixed dyslipidemia: evaluation of dose response.
Ferdinand KC; Davidson MH; Kelly MT; Setze CM
Am J Cardiovasc Drugs; 2012 Apr; 12(2):117-25. PubMed ID: 22263674
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the Effect of Rosuvastatin 2.5 mg vs 20 mg on Coronary Plaque Determined by Angioscopy and Intravascular Ultrasound in Japanese With Stable Angina Pectoris (from the Aggressive Lipid-Lowering Treatment Approach Using Intensive Rosuvastatin for Vulnerable Coronary Artery Plaque [ALTAIR] Randomized Trial).
Takayama T; Komatsu S; Ueda Y; Fukushima S; Hiro T; Hirayama A; Saito S;
Am J Cardiol; 2016 Apr; 117(8):1206-12. PubMed ID: 26879069
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial.
Farnier M; Jones P; Severance R; Averna M; Steinhagen-Thiessen E; Colhoun HM; Du Y; Hanotin C; Donahue S
Atherosclerosis; 2016 Jan; 244():138-46. PubMed ID: 26638010
[TBL] [Abstract][Full Text] [Related]
9. The impact of the time of drug administration on the effectiveness of combined treatment of hypercholesterolemia with Rosuvastatin and Ezetimibe (RosEze): study protocol for a randomized controlled trial.
Obońska K; Kasprzak M; Sikora J; Obońska E; Racki K; Goździkiewicz N; Krintus M; Kubica J
Trials; 2017 Jul; 18(1):316. PubMed ID: 28697767
[TBL] [Abstract][Full Text] [Related]
10. A Phase III, Multicenter, Randomized, Double-blind, Active Comparator Clinical Trial to Compare the Efficacy and Safety of Combination Therapy With Ezetimibe and Rosuvastatin Versus Rosuvastatin Monotherapy in Patients With Hypercholesterolemia: I-ROSETTE (Ildong Rosuvastatin & Ezetimibe for Hypercholesterolemia) Randomized Controlled Trial.
Hong SJ; Jeong HS; Ahn JC; Cha DH; Won KH; Kim W; Cho SK; Kim SY; Yoo BS; Sung KC; Rha SW; Shin JH; Han KR; Chung WS; Hyon MS; Lee HC; Bae JH; Rhee MY; Kwan J; Jeon DW; Yoo KD; Kim HS
Clin Ther; 2018 Feb; 40(2):226-241.e4. PubMed ID: 29402522
[TBL] [Abstract][Full Text] [Related]
11. Lipid lowering efficacy and safety of Ezetimibe combined with rosuvastatin compared with titrating rosuvastatin monotherapy in HIV-positive patients.
Saeedi R; Johns K; Frohlich J; Bennett MT; Bondy G
Lipids Health Dis; 2015 Jun; 14():57. PubMed ID: 26087958
[TBL] [Abstract][Full Text] [Related]
12. High-dose statin therapy with rosuvastatin reduces small dense LDL and MDA-LDL: The Standard versus high-dose therApy with Rosuvastatin for lipiD lowering (SARD) trial.
Nishikido T; Oyama J; Keida T; Ohira H; Node K
J Cardiol; 2016 Apr; 67(4):340-6. PubMed ID: 26162946
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Adding Omega-3 Fatty Acids in Statin-treated Patients with Residual Hypertriglyceridemia: ROMANTIC (Rosuvastatin-OMAcor iN residual hyperTrIglyCeridemia), a Randomized, Double-blind, and Placebo-controlled Trial.
Kim CH; Han KA; Yu J; Lee SH; Jeon HK; Kim SH; Kim SY; Han KH; Won K; Kim DB; Lee KJ; Min K; Byun DW; Lim SW; Ahn CW; Kim S; Hong YJ; Sung J; Hur SH; Hong SJ; Lim HS; Park IB; Kim IJ; Lee H; Kim HS
Clin Ther; 2018 Jan; 40(1):83-94. PubMed ID: 29223557
[TBL] [Abstract][Full Text] [Related]
14. A randomized, controlled comparison of different intensive lipid-lowering therapies in Chinese patients with non-ST-elevation acute coronary syndrome (NSTE-ACS): Ezetimibe and rosuvastatin versus high-dose rosuvastatin.
Ran D; Nie HJ; Gao YL; Deng SB; Du JL; Liu YJ; Jing XD; She Q
Int J Cardiol; 2017 May; 235():49-55. PubMed ID: 28291622
[TBL] [Abstract][Full Text] [Related]
15. The Ratio of Eicosapentaenoic Acid (EPA) to Arachidonic Acid may be a Residual Risk Marker in Stable Coronary Artery Disease Patients Receiving Treatment with Statin Following EPA Therapy.
Tani S; Nagao K; Kawauchi K; Yagi T; Atsumi W; Matsuo R; Hirayama A
Am J Cardiovasc Drugs; 2017 Oct; 17(5):409-420. PubMed ID: 28634822
[TBL] [Abstract][Full Text] [Related]
16. Effect of eicosapentaenoic acid/docosahexaenoic acid on coronary high-intensity plaques detected with non-contrast T1-weighted imaging (the AQUAMARINE EPA/DHA study): study protocol for a randomized controlled trial.
Nakao K; Noguchi T; Asaumi Y; Morita Y; Kanaya T; Fujino M; Hosoda H; Yoneda S; Kawakami S; Nagai T; Nishihira K; Nakashima T; Kumasaka R; Arakawa T; Otsuka F; Nakanishi M; Kataoka Y; Tahara Y; Goto Y; Yamamoto H; Hamasaki T; Yasuda S
Trials; 2018 Jan; 19(1):12. PubMed ID: 29310688
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of a generic rosuvastatin in a real-world setting: prospective, observational clinical study in Lebanese patients.
Betto M; Fares J; Saliba N; Ballout H
Ann Saudi Med; 2017; 37(5):366-374. PubMed ID: 28988251
[TBL] [Abstract][Full Text] [Related]
18. Administration of eicosapentaenoic acid may alter high-density lipoprotein heterogeneity in statin-treated patients with stable coronary artery disease: A 6-month randomized trial.
Tani S; Matsuo R; Yagi T; Matsumoto N
J Cardiol; 2020 Mar; 75(3):282-288. PubMed ID: 31543378
[TBL] [Abstract][Full Text] [Related]
19. Comparative effects of high-dose atorvastatin versus moderate-dose rosuvastatin on lipid parameters, oxidized-LDL and inflammatory markers in ST elevation myocardial infarction.
Aydin MU; Aygul N; Altunkeser BB; Unlu A; Taner A
Atherosclerosis; 2015 Apr; 239(2):439-43. PubMed ID: 25697576
[TBL] [Abstract][Full Text] [Related]
20. Plasma VEGF and IL-8 Levels in Patients with Mixed Dyslipidaemia. Effect of Rosuvastatin Monotherapy or its Combination at a Lower Dose with Omega-3 Fatty Acids: A Pilot Study.
Chantzichristos VG; Agouridis AP; Moutzouri E; Stellos K; Elisaf MS; Tselepis AD
Curr Vasc Pharmacol; 2016; 14(5):474-480. PubMed ID: 27041244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
